May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an 5ß1 Integrin Antagonist
Author Affiliations & Notes
  • N. Umeda
    Wilmer Eye Institute, Baltimore, MD
  • S. Kachi
    Wilmer Eye Institute, Baltimore, MD
  • H. Akiyama
    Wilmer Eye Institute, Baltimore, MD
  • G. Zahn
    Jerini Pharmaceuticals, Berlin, Germany
  • R. Stragies
    Jerini Pharmaceuticals, Berlin, Germany
  • P.A. Campochiaro
    Wilmer Eye Institute, Baltimore, MD
  • Footnotes
    Commercial Relationships  N. Umeda, None; S. Kachi, None; H. Akiyama, None; G. Zahn, None; R. Stragies, None; P.A. Campochiaro, None.
  • Footnotes
    Support  by the Foundation Fighting Blindness, the Macula Vision Foundation, and Dr. and Mrs. William Lake. PAC is the George S. and Dolores Dore Eccles Professor of Ophthalmology.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 899. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Umeda, S. Kachi, H. Akiyama, G. Zahn, R. Stragies, P.A. Campochiaro; Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an 5ß1 Integrin Antagonist . Invest. Ophthalmol. Vis. Sci. 2006;47(13):899.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Integrin α5ß1 plays an important role in developmental angiogenesis, but its role in various types of pathologic neovascularization has not been completely defined.

Methods: : The effect of JSM6427, a selective α5ß1 antagonist, was quantitatively assessed in mice with choroidal neovascularization due to laser–induced rupture of Bruch's membrane.

Results: : In this study, we found strong upregulation of α5ß1 in choroidal neovascularization. Implantation of an osmotic pump delivering 1.5 or 10 µ/hour (∼1.8 or 12 mg/kg/day) of JSM6427 caused significant suppression of choroidal neovascularization; the area of neovascularization was reduced by 33 to 40%. When an osmotic pump delivering 10 µg/hour of JSM6427 was implanted 7 days after rupture of Bruch's membrane, there was TUNEL staining in vascular cells within the neovascularization and significant regression of the neovascularization over the next week.

Conclusions: : These data suggest that α5ß1 plays a role in the development and maintenance of choroidal neovascularization and provides a target for therapeutic intervention.

Keywords: choroid: neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×